IKK16 also abrogates resistance of glioblastoma U87MG cells to the Gefitinib+PHA665752 (a MET inhibitor) treatment via blocking fibroblast growth factor 1 (FGF1) expression [49]. The gene discussed is MET; the disease is glioblastoma.